The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 801–900 of 1,056
Spatial regulation of controlled bioactive factor delivery for bone tissue engineering
Samorezov, J. E., & Alsberg, E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.11.018 · Cited by 153
“BMP-2, TGF-β1, FGF-2 and VEGF all exhibit heparin affinity [137–139], and exploiting these interactions can yield more delayed release systems for bone tissue engineering.”
BackgroundLorenc, P., Sikorska, A., Molenda, S., Guzniczak, N., Dams‐Kozlowska, H., & Florczak, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117585 · Cited by 153
Bryan, B. A., Walshe, T. E., Mitchell, D., Havumaki, J. S., Saint‐Geniez, M., Maharaj, A. S. R., Maldonado, A. E., & D'Amore, P. A. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0856 · Cited by 156
“Moreover, although VEGF is well established as a modulator of blood vessel formation (Ferrara et al., 2003), the expression of VEGF receptors by many cell types in addition to EC points to nonvascular roles for VEGF in the adult (Maharaj et al., 2006; D’Amore, 2007).”
BackgroundInfluentialCurrent Treatments for Advanced Stage Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Socinski, M. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-110lc · Cited by 152
Liu, S., Zhang, H., Zhang, X., Lu, W., Huang, X., Xie, H., Zhou, J., Wang, W., Zhang, Y., Liu, Y., et al. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0331 · Cited by 138
“VEGF was also shown to enhance cell proliferation and angiogenesis.(37) Moreover, the structurally and functionally different molecules in the ECM scaffolds may support the proliferation and secretion of growth factors by the seeded cells.”
eNOS derived nitric oxide regulates endothelial barrier function via VE cadherin and Rho GTPases
Lorenzo, A. D., Lin, M. I., Murata, T., Landskroner-Eiger, S., Schleicher, M., Kothiya, M., Iwakiri, Y., Yu, J., Huang, P. L., & Sessa, W. C. (2013) · Journal of Cell Science · doi:10.1242/jcs.115972 · Cited by 144
“essential role in both physiological and pathological angiogenesis (Ferrara et al., 2003).”
BackgroundMast cell–derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors
Nakayama, T., Yao, L., & Tosato, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422089 · Cited by 139
“Using RT-PCR, we examined mast cell and plasmacytoma cell expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D, placental growth factor (PlGF), Ang-1, and Ang-2, molecules known to regulate endothelial cell function and angiogenesis (22, 23).”
MethodZeng, G., Taylor, S. M., McColm, J. R., Kappas, N. C., Kearney, J. B., Williams, L. H., Hartnett, M. E., & Bautch, V. L. (2006) · Blood · doi:10.1182/blood-2006-07-037952 · Cited by 147
Regulation of angiogenesis: apoptotic cues from the ECM
Cheresh, D. A., & Stupack, D. G. (2008) · Oncogene · doi:10.1038/onc.2008.304 · Cited by 149
“VEGFs are wellstudied growth factors that bind to cell surface heparin, neuropilin and to the receptor tyrosine kinases Flk-1, Flt-1 and Flt-3, depending upon the particular VEGF isoform (A, B, C and D) or splice variant (Ferrara et al., 2003).”
BackgroundApatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
Peng, H., Zhang, Q., Li, J., Zhang, N., Hua, Y., Xu, L., Deng, Y., Lai, J., Peng, Z., Peng, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7948 · Cited by 140
“In addition to its well-known angiogenic effect, VEGF may regulate tumor growth through direct binding to VEGFRs present on cancer cells themselves [21].”
Dang, W., Ma, B., Li, B., Huan, Z., Ma, N., Zhu, H., Chang, J., Xiao, Y., & Wu, C. (2020) · Biofabrication · doi:10.1088/1758-5090/ab5ae3 · Cited by 138
Chen, C., Hung, H., & Hsu, S. (2008) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20589 · Cited by 141
“VEGF can play a special role on EC via VEGFR1 (Flt-1) and VEGFR2 (Flk-1/ KDR) to induce vascular permeability, cellular proliferation, cellular migration, and tube formation [57].”
BackgroundTwo‐Dimensional Multiarray Formation of Hepatocyte Spheroids on a Microfabricated PEG‐Brush Surface
Otsuka, H., Hirano, A., Nagasaki, Y., Okano, T., Horiike, Y., & Kataoka, K. (2004) · ChemBioChem · doi:10.1002/cbic.200300822 · Cited by 140
Tumor lymphangiogenesis and metastatic spread—New players begin to emerge
Achen, M. G., & Stacker, S. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21899 · Cited by 140
“VEGF-A is a secreted angiogenic protein that activates VEGFR-1 and VEGFR-2, cell surface receptor tyrosine kinases expressed on the endothelium of blood vessels.(88) It has been reported that VEGFR-2 can also be expressed on the endothelium of some lymphatic vessels,(89) raising the possibility that it could signal fo…”
BackgroundMolecular lymphangiogenesis: new players
Tammela, T., Petrova, T. V., & Alitalo, K. K. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.06.004 · Cited by 163
de Paulis, A., Prevete, N., Fiorentino, I., Rossi, F. W., Staibano, S., Montuori, N., Ragno, P., Longobardi, A., Liccardo, B., Genovese, A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7322 · Cited by 140
Targeting Aggressive Cancer Stem Cells in Glioblastoma
Seymour, T., Nowak, A. K., & Kakulas, F. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00159 · Cited by 139
“A characteristic of the recurrent tumors is high expression of vascular endothelial growth factor (VEGF), which has been associated with poor prognosis as it promotes angiogenesis and tumor growth (25).”
BackgroundThe netrin receptor UNC5B promotes angiogenesis in specific vascular beds
Navankasattusas, S., Whitehead, K. J., Suli, A., Sorensen, L. K., Lim, A. H., Zhao, J., Park, K. W., Wythe, J. D., Thomas, K. R., Chien, C.-B., et al. (2008) · Development · doi:10.1242/dev.013623 · Cited by 127
“Thus, in contrast to VEGF signaling, which has profound effects on virtually all endothelial cells and vascular beds during developmental angiogenesis (Ferrara et al., 2003), guidance cues in general and UNC5B specifically, may provide an additional level of regulation to coordinate the spatial and temporal organizati…”
BackgroundSönmez, K., Drenser, K. A., Capone, A., & Trese, M. T. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.050 · Cited by 151
Hohenstein, A., Erber, R., Schilling, L., & Weigel, R. (2005) · Journal of Neurotrauma · doi:10.1089/neu.2005.22.518 · Cited by 142
“The VEGFR-2 receptor is the major factor in eliciting the mitogenic, angiogenic, and permeability-enhancing effect of VEGF as reviewed elsewhere (Ferrara et al., 2003).”
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells
Guo, S., Liu, M., Wang, G., Torroella‐Kouri, M., & Gonzalez-Perez, R. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.002 · Cited by 160
“Signals triggered by VEGF (a major angiogenic factor) binding to its receptor, VEGFR-2 is required for normal and pathological proliferation, migration and differentiation of endothelial cells [114,115].”
BackgroundLigand‐Stimulated VEGFR2 Signaling is Regulated by Co‐Ordinated Trafficking and Proteolysis
Bruns, A. F., Herbert, S. P., Odell, A. F., Jopling, H. M., Hooper, N. M., Zachary, I. C., Walker, J. H., & Ponnambalam, S. (2010) · Traffic · doi:10.1111/j.1600-0854.2009.01001.x · Cited by 135
“One strategy for blocking solid tumor metastasis is using anti-angiogenesis drugs such as Avastatin (a humanized monoclonal antibody specific for VEGF-A) or Sutent (a VEGF receptor tyrosine kinase inhibitor) (1,4).”
BackgroundInfluentialMokas, S., Larivière, R., Lamalice, L., Gobeil, S., Cornfield, D. N., Agharazii, M., & Richard, D. E. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.020 · Cited by 144
“HiPO4-induced HIF-1 activation leads to target gene expression, including VEGF, a key angiogenic factor.(53,54) VEGF is expressed in osteoblast precursor cells and is known to stimulate osteoblast differentiation and bone formation.”
BackgroundTargeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 143
Varker, K. A., Biber, J. L., Kefauver, C. A., Jensen, R. R., Lehman, A., Young, D. C., Wu, H. M., Lesinski, G. B., Kendra, K. L., Chen, H. X., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9389-5 · Cited by 139
“3 Endothelial cells express a family of tyrosine receptor kinases that bind VEGF with high affinity(4) and stimulate several signaling pathways that induce endothelial cell mitosis and migration.(5) VEGF also promotes the survival of newly formed blood vessels.”
BackgroundHlushchuk, R., Riesterer, O., Baum, O., Wood, J. M., Gruber, G., Pruschy, M. N., & Djonov, V. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071131 · Cited by 139
“Many human neoplasms and animal tumor models express high mRNA and protein levels of VEGF.(2,8,9) Inhibition of VEGF or of its receptors should block the downstream cascade and interfere with its pro-angiogenic effects and thereby block tumor vascularization.”
BackgroundAwada, H. K., Johnson, N. R., & Wang, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.034 · Cited by 138
“VEGF, an endothelial-specific factor, triggers the process through endothelial cell (EC) sprouting, proliferation, migration, and lumen formation, and is thus primarily needed in the first few days of angiogenesis [17, 19, 20].”
BackgroundCovassin, L., Siekmann, A. F., Kacergis, M. C., Laver, E., Moore, J. C., Villefranc, J. A., Weinstein, B. M., & Lawson, N. D. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.02.031 · Cited by 146
“Furthermore, Vegf-A is also required for angiogenic sprouting and plays an important role in modulating vascular permeability in both adult and embryonic stages (Bates and Harper, 2002; Ferrara et al., 2003).”
Feigl, B. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.004 · Cited by 149
“Besides being a stimulating factor in angiogenesis, VEGF is known to increase vascular permeability in existing blood vessels and enhances inflammatory responses (Ferrara et al., 2003).”
BackgroundLake, A. C., Vassy, R., Benedetto, M. D., Lavigne, D., Visage, C. L., Perret, G. Y., & Letourneur, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600686200 · Cited by 144
A Hybrid Model for Three-Dimensional Simulations of Sprouting Angiogenesis
Milde, F., Bergdorf, M., & Koumoutsakos, P. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.124511 · Cited by 138
Signaling pathways in the development of infantile hemangioma
Ji, Y., Chen, S., Li, K., Li, L., Xu, C., & Xiang, B. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-13 · Cited by 145
“The genetic deletion of VEGF-A or its primary signaling receptor VEGFR-2 results in early embryonic lethality, associated with a near-complete block of hematopoietic and vascular development [37].”
BackgroundKo, S. Y., Lee, W., Kenny, H. A., Dang, L. H., Ellis, L. M., Jonasch, E. W., Lengyel, E. R., & Naora, H. (2019) · Communications Biology · doi:10.1038/s42003-019-0609-x · Cited by 147
The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review
Li, L., Chen, C., Chiang, C., Xiao, T., Chen, Y., Zhao, Y., & Zheng, D. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59918 · Cited by 141
“In the context of cancer, VEGF can be released from tumor cells or the tumor-related ECM and binds to VEGFR1/2 to induce the proliferation of vascular endothelial cells [157].”
BackgroundSelective Regulation of Arterial Branching Morphogenesis by Synectin
Chittenden, T. W., Claes, F., Lanahan, A. A., Autiero, M., Palac, R. T., Tkachenko, E., Elfenbein, A., de Almodóvar, C. R., Dedkov, E. I., Tomanek, R. J., et al. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.03.012 · Cited by 137
Murga, M., Fernández-Capetillo, Ó., & Tosato, G. (2004) · Blood · doi:10.1182/blood-2004-07-2598 · Cited by 137
“Cells were plated (4000 cells/well; 96 well plates; in 0.2 ml M199 supplemented with 18% heat inactivated FBS) with or without 1-100 ng/ml VEGF.”
BackgroundResultInfluentialChemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish
Bayliss, P. E., Bellavance, K. L., Whitehead, G. G., Abrams, J., Aegerter, S., Robbins, H. S., Cowan, D. B., Keating, M. T., O’Reilly, T., Wood, J. M., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio778 · Cited by 138
“The vascular endothelial growth factor (VEGF) ligands and receptors play critical roles in regulating physiological and pathological angiogenesi”
BackgroundInfanger, M., Kossmehl, P. P., Shakibaei, M., Baatout, S., Witzing, A., Grosse, J., Bauer, J. W., Cogoli, A., Faramarzi, S., Derradji, H., et al. (2006) · APOPTOSIS · doi:10.1007/s10495-006-5697-7 · Cited by 146
Differential regulation of blood vessel formation between standard and delayed bone healing
Lienau, J., Schmidt‐Bleek, K., Peters, A., Haschke, F., Duda, G. N., Perka, C., Bail, H. J., Schütze, N., Jakob, F., & Schell, H. (2009) · Journal of Orthopaedic Research · doi:10.1002/jor.20870 · Cited by 134
“VEGF mediates angiogenesis mainly via signaling through VEGFR2, whereas the VEGFR1 is supposed to be a negative regulator of the VEGF activity by preventing its interaction with VEGFR2.”
InfluentialVEGF improves survival of mesenchymal stem cells in infarcted hearts
Pons, J., Huang, Y., Arakawa-Hoyt, J. S., Washko, D., Takagawa, J., Ye, J., Grossman, W., & Su, H. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.003 · Cited by 137
“In addition to its potent angiogenic functions, VEGF can stimulate proliferation, delay senescence, suppress apoptosis and promote survival of various cells [15].”
BackgroundPhysiologic Angiodynamics in the Brain
Dore-Duffy, P., & La Manna, J. C. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1713 · Cited by 132
“Vascular endothelial growth factor (VEGF) is one such gene that is upregulated by HIF-1 and that plays an important role in capillary angiogenesis (30).”
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Clarke, J. M., & Hurwitz, H. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.810717 · Cited by 142
“The VEGF family includes VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and placental growth factor (PlGF) with three receptors: VEGFR1 (fms-like tyrosine kinase 1/Flt-1), VEGFR2 (Flk-1/KDR), and VEGFR3 (Flt-4) with associated co-receptors neuropillin 1 and 2 (NRP1/2) (see Figure 1) [8].”
BackgroundTargeting non-malignant disorders with tyrosine kinase inhibitors
Grimminger, F., SCHERMULY, R. T., & Ghofrani, H. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3297 · Cited by 143
“These include renal cell carcinoma, lung cancer, breast cancer, colon cancer, hepatoma, bladder cancer, gastric cancer and prostate cance”
BackgroundNeural Progenitor Cells Treated with EPO Induce Angiogenesis through the Production of Vegf
Wang, L., Chopp, M., Gregg, S. R., Zhang, R. L., Teng, H., Jiang, A., Feng, Y., & Zhang, Z. G. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.32 · Cited by 135
“Among them, VEGF A and its receptor VEGFR2 are required to initiate the formation of immature vessels by vasculogenesis or angiogenesis during embryonic development (Ferrara et al, 2003).”
BackgroundPang, X., Yi, T., Yi, Z., Cho, S., Qu, W., Pinkaew, D., Fujise, K., & Liu, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2531 · Cited by 137
Pandit, J., Sultana, Y., & Aqil, M. (2017) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2016.1243545 · Cited by 134
“There are four active isomers of VEGF-A consisting of 121, 165, 189, and 206 amino acids (Ferrara et al. 2003).”
BackgroundXu, Y., Lü, X., Hu, Y., Yang, B., Tsui, C., Yu, S., Lü, L., & Liang, X. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12473 · Cited by 137
Therapeutically relevant aspects in bone repair and regeneration
Pérez, R. A., Seo, S.-J., Won, J., Lee, E., Jang, J.-H., Knowles, J. C., & Kim, H. (2015) · Materials Today · doi:10.1016/j.mattod.2015.06.011 · Cited by 149
Fibroblast-Type Reticular Stromal Cells Regulate the Lymph Node Vasculature
Chyou, S., Ekland, E. H., Carpenter, A. C., Tzeng, T.-C. J., Tian, S., Michaud, M., Madri, J. A., & Lu, T. T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3887 · Cited by 131
Ehrbar, M., Zeisberger, S. M., Raeber, G. P., Hubbell, J. A., Schnell, C., & Zisch, A. H. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.002 · Cited by 136
Trentin, D., Hall, H., Wechsler, S., & Hubbell, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505964102 · Cited by 148
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
Suzuki, H. Y., Onishi, H., 和田, 純., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., & Katano, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200939887 · Cited by 136
Weijts, B. G. M. W., Bakker, W. J., Cornelissen, P. W. A., Liang, K.-H., Schaftenaar, F. H., Westendorp, B., de Wolf, C. A. C. M. T., Paciejewska, M., Scheele, C. L. G. J., Kent, L. N., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.231 · Cited by 138
“From these findings, we conclude that inactivation of atypical E2fs in zebrafish impairs VegfAa expression, a critical regulator of angiogenesis (Ferrara et al , 2003).”
InfluentialPratheeshkumar, P., Son, Y., Budhraja, A., Wang, X., Ding, S., Wang, L., Hitron, J. A., Lee, J., Kim, D., Divya, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052279 · Cited by 140
“VEGFR2 mediates the majority of the downstream effects of VEGF in angiogenesis.”
BackgroundInfluentialLi, W., Man, X., Li, C., Chen, J., Zhou, J., Cai, S., Lu, Z., & Zheng, M. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.05.003 · Cited by 135
Centanin, L., Dekanty, A., Romero, N. M., Irisarri, M., Gorr, T. A., & Wappner, P. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.020 · Cited by 150
“…from pre-existing blood vessels, and it is triggered when hypoxic cells secrete angiogenic growth factors, mainly the Vascular Endothelial Growth Factor (VEGF), which binds its receptors on the endothelial cells of blood vessels (Ferrara et al., 2003; Levy et al., 1995; Shweiki et al., 1992).”
BackgroundTejada, M. L., Yu, L., Dong, J., Jung, K., Meng, G., Peale, F. V., Frantz, G. D., Hall, L., Liang, X., Gerber, H.-P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1770 · Cited by 127
Self-citationEhrlich, R., Harris, A., Ciulla, T. A., Kheradiya, N., Winston, D. M., & Wirostko, B. M. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01501.x · Cited by 143
“Stimulation with either VEGF-A165 or endothelial platelet-activating factor (PAF) can induce a rapid and transient phosphorylation of VE-cadherin, disorganization of the endothelial junction proteins and dissociation of the adherens junction, leading to gap formation and increased permeability (Fig.”
BackgroundInfluentialFibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
Welti, J. C., Gourlaouen, M., Powles, T. B., Kudahetti, S. C., Wilson, P. A., Berney, D. M., & Reynolds, A. R. (2010) · Oncogene · doi:10.1038/onc.2010.503 · Cited by 141
“VEGF-A drives angiogenesis by signalling through two cognate receptors on local endothelial cells, VEGFR1 and VEGFR2 (Ferrara et al., 2003; Olsson et al., 2006).”
Tocotrienols fight cancer by targeting multiple cell signaling pathways
Kannappan, R., Gupta, S. C., Kim, J. H., & Aggarwal, B. B. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0220-3 · Cited by 139
“Because VEGF receptor-2 is the key protein in growth factor signal transduction in endothelial cells ( Ferrara et al. 2003 ), regulation of VEGFR-2 activation is a potential molecular target of antiangiogenic compounds (Schlaeppi and Wood 1999).”
BackgroundPlacental Mesenchymal Stromal Cells Rescue Ambulation in Ovine Myelomeningocele
Wang, A., Brown, E. G., Lankford, L., Keller, B. A., Pivetti, C. D., Zelin, N. S., Beattie, M. S., Bresnahan, J. C., & Farmer, D. L. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0296 · Cited by 145
Biomaterials for Bioprinting Microvasculature
Barrs, R. W., Jia, J., Silver, S. E., Yost, M. J., & Mei, Y. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00027 · Cited by 140
Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells
Riboldi, E., Musso, T., Moroni, E., Urbinati, C., Bernasconi, S., Rusnati, M., Adorini, L., Presta, M., & Sozzani, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2788 · Cited by 134
Cabebe, E. C., & Wakelee, H. A. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0022-4 · Cited by 143
Wu, D., Zhau, H. E., Huang, W.-C., Iqbal, S. A., Habib, F. K., Sartor, O. A., Cvitanovic, L., Marshall, F. F., Xu, Z., & Chung, L. W. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210316 · Cited by 140
“VEGF165 is the predominant isoform, with optimal bioavailability and is responsible for VEGF biological potency (Ferrara et al., 2003).”
BackgroundChung, J. Y., Song, Y., Wang, Y., Magness, R. R., & Zheng, J. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031580 · Cited by 134
Molecular Parallels between Neural and Vascular Development
Eichmann, A., & Thomas, J.-L. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006551 · Cited by 133
“Third, in addition to their role in angiogenesis, VEGF family members emerge as potent regulators of neurogenesis and neural plasticity and represent, together with their receptors, therapeutic targets for neural tissue repair and neurodegenerative disease (Ferrara et al. 2003; Storkebaum and Carmeliet 2004; Ruiz de A…”
VEGF and bone cell signalling: an essential vessel for communication?
Clarkin, C., & Gerstenfeld, L. C. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2911 · Cited by 144
“The most studied member of the family (VEGF-A) is one of the main promoters of both physiological and pathological angiogenesis that belongs to a family of homodimeric proteins consisting of six members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor.(25,26) VEGF-A exists as several protein isoforms.”
BackgroundSpatiotemporal control over growth factor signaling for therapeutic neovascularization☆
Cao, L., & Mooney, D. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.012 · Cited by 133
“In addition, the different isoforms of VEGF-A, all of which are important in vessel development, are distinguished by their differential binding affinity to the extracellular matrix [40].”
BackgroundBhide, R. S., Cai, Z., Zhang, Y., Qian, L., Wei, D. D., Barbosa, S. A. L., Lombardo, L. J., Borzilleri, R. M., Zheng, X., Wu, L. I., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051106d · Cited by 133
miR-203 Suppresses Tumor Growth and Angiogenesis by Targeting VEGFA in Cervical Cancer
Zhu, X., Er, K., Mao, C., Qi, Y., Xu, H., Zhang, Y., Zhu, J., Cui, F., Zhao, W., & Shi, H. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350125 · Cited by 138
Vascular endothelial growth factor control mechanisms in skeletal growth and repair
Hu, K., & Olsen, B. R. (2016) · Developmental Dynamics · doi:10.1002/dvdy.24463 · Cited by 144
“Membrane-bound VEGFR1 serves either as a decoy receptor for VEGF in endothelial cells, particularly in tumor endothelium (Ferrara et al., 2003; Jinnin et al., 2008), or as a signaling receptor like VEGFR2, such as in VEGF-induced monocyte migration (Barleon et al.”
BackgroundInfluentialAntiangiogenic Effect of Flavonoids and Chalcones: An Update
Mirossay, L., Varinská, L., & Mojžíš, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010027 · Cited by 139
“, proliferation, migration or tube formation) [50].”
Novel Function for Vascular Endothelial Growth Factor Receptor-1 on Epidermal Keratinocytes
Wilgus, T. A., Matthies, A. M., Radek, K. A., Dovi, J. V., Burns, A. L., Shankar, R., & DiPietro, L. A. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61213-8 · Cited by 133
“VEGF binds two high-affinity tyrosine kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR).(21) Signaling through these receptors mediates the actions of endothelial cells required for angiogenesis.”
BackgroundYao, X., Ping, Y., Liu, Y., Chen, K., Yoshimura, T., Liu, M., Gong, W., Chen, C., Niu, Q., Guo, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057188 · Cited by 132
“VEGFR-2 (also known as KDR or Flk-1) is a high-affinity receptor for VEGF and is the most important molecule for angiogenesis and vasculogenesis by mediating almost all cellular response to VEGF [42].”
BackgroundAngiogenesis in Inflammatory Bowel Disease
Alkim, C. A., Alkım, H., Köksal, A. R., Boğa, S., & Şen, İ. (2015) · International Journal of Inflammation · doi:10.1155/2015/970890 · Cited by 140
“VEGF-A has got four major isoforms; VEGF 165 is the major contributor of pathological angiogenesis and exerts its effect by binding to VEGFR2 and neuropilin-1 [24, 25].”
BackgroundCritical role of TRPC6 channels in VEGF-mediated angiogenesis
Ge, R., Tai, Y., Sun, Y., Zhou, K., Yang, S., Cheng, T., Zou, Q., Shen, F., & Wang, Y. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.023 · Cited by 132
“Binding of VEGF to VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1), two receptors for VEGF with intrinsic tyrosine kinase activity, leads to activation of phospholipase-C (PLC), PKC, andMAP-kinase and VEGF promotes angiogenesis through activation of VEGFR2 [1–4].”
BackgroundDynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers
Ghanaati, S., Webber, M. J., Unger, R. E., Orth, C., Hulvat, J. F., Kiehna, S. E., Barbeck, M., Rasic, A., Stupp, S. I., & Kirkpatrick, C. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.063 · Cited by 131
Treatments for Corneal Neovascularization: A Review
Gupta, D., & Illingworth, C. (2011) · Cornea · doi:10.1097/ico.0b013e318201405a · Cited by 138
Du, R., Petritsch, C., Lu, K., Liu, P., Haller, A., Ganss, R., Song, H., Vandenberg, S., & Bergers, G. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-001 · Cited by 129
Zimmermann, R. C., Hartman, T. D., Kavic, S., Pauli, S. A., Böhlen, P., Sauer, M. V., & Kitajewski, J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18740 · Cited by 133
Eskander, R. N., & Tewari, K. S. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.029 · Cited by 133
“and have been identified as potential targets for drug development [39,40].”
BackgroundSmall, H. Y., Montezano, A. C. I., Rios, F. J. O., Savoia, C., & Touyz, R. M. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.011 · Cited by 131
Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth
Ryeom, S. W., Baek, K., Rioth, M. J., Lynch, R. C., Zaslavsky, A., Birsner, A. E., Yoon, S. S., & McKeon, F. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.018 · Cited by 143
Duan, J., Yu, Y., Yu, Y., Yang, L., Huang, P., Zhou, X., Peng, S., & Sun, Z. (2014) · Particle and Fibre Toxicology · doi:10.1186/s12989-014-0050-8 · Cited by 136
“The vascular endothelial growth factor (VEGF) bound with the receptor tyrosine kinases VEGFR2, mediating its biological effects on angiogenesis [37].”
BackgroundWang, H., Ran, H.-F., Yin, Y., Xu, X., Jiang, B.-X., Yu, S.-Q., Chen, Y., Ren, H., Feng, S., Zhang, J., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00803-4 · Cited by 136
“There are much evidences that VEGFR2 delivers key mitogenic, angiogenic and permeability-enhancing signals of VEGF, and is the major mediator of endothelial cells mitogenesis and survival, as well as angiogenesis and microvascular permeability [23, 24].”
BackgroundAngiogenesis in cancer: molecular mechanisms, clinical impact
Eichhorn, M., Kleespies, A., Angele, M. K., Jauch, K. ‐., & Bruns, C. J. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0150-0 · Cited by 153
“The VEGF family activates endothelial cells by signaling through the VEGF receptors (VEGFR-1, -2, -3) [12] (Fig.”
Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b
Ciais, D., Cherradi, N., Bailly, S., Grenier, E., Berra, E., Pouysségur, J., LaMarre, J., & Feige, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207939 · Cited by 132
“Among the dozen of angiogenic factors characterized to date, vascular endothelial growth factor (VEGF) has emerged as the most important regulator of physiological and pathological angiogenesis (Ferrara et al., 2003).”
BackgroundBaffert, F., Thurston, G., Rochon-Duck, M., Le, T., Brekken, R., & McDonald, D. M. (2004) · Circulation Research · doi:10.1161/01.res.0000125295.43813.1f · Cited by 128
“The measurement involved three steps: (1) 480 640 pixel RGB color images of capillaries were acquired with a background fluorescence (nonspecific fluorescence) set at a constant level by adjusting the gain of the CCD camera; (2) color images were converted to 8-bit gray scale (fluorescence intensity from 0 to 255) usi…”
MethodClinical implications for Vascular Endothelial Growth Factor in the lung: friend or foe?
Papaioannou, A. Ι., Κostikas, Κ., Κollia, P., & Gourgoulianis, K. I. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-128 · Cited by 132
“Other studies have shown that the product of the von Hippel-Lindau (VHL) tumor suppressor gene plays an important role in HIF-1 dependent hypoxic responses and provides negative regulation of many hypoxia inducible genes, including VEGF gene [5].”
InfluentialChen, H., Li, L., Wang, S., Lei, Y., Ge, Q., Lv, N., Zhou, X., & Chen, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2662 · Cited by 130
“Lots of evidences showed that VEGF significantly promoted the division, proliferation, and migration of endothelial cells [54, 55].”
Shimizu, M., Shirakami, Y., Sakai, H., Yasuda, Y., Kubota, M., Adachi, S., Tsurumi, H., Hara, Y., & Moriwaki, H. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.03.036 · Cited by 138
A Review of Vasculogenesis Models
Ambrosi, D., Bussolino, F., & Preziosi, L. (2004) · Computational and Mathematical Methods in Medicine · doi:10.1080/1027366042000327098 · Cited by 130
“A good candidate as a soluble chemotactic mediator is VEGF-A, which is known to induce EC growth, survival, and motility [26, 28].”
BackgroundUnraveling the Anticancer Effect of Curcumin and Resveratrol
Pavan, A. R., Silva, G., Jornada, D. H., Chiba, D. E., Fernandes, G., Chin, C. M., & dos Santos, J. L. (2016) · Nutrients · doi:10.3390/nu8110628 · Cited by 140
“These growth factors regulate a family VEGF receptors tyrosine kinases (VEGFR-1, VEGFR-2 and VEGFR-3) and promote endothelium regeneration, blood vessel regeneration and increase vascular permeability.”
BackgroundInfluentialCheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 142
Hsieh, M., Boerboom, D., Shimada, M., Lo, Y., Parlow, A. F., Luhmann, U. F. O., Berger, W., & Richards, J. S. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.042739 · Cited by 139
“As shown, the expression of Vegfa and Vegfc mRNA was significantly reduced in the Fzd4 / compared to the Fzd4þ/þ ovaries on all days analyzed.”
BackgroundInfluentialAhlers, C., Götzinger, E., Pircher, M., Golbaz, I., Prager, F., Schütze, C., Baumann, B., Hitzenberger, C. K. F., & Schmidt-Erfurth, U. M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3817 · Cited by 129
“Although these facts are alarming, only 1 in 10 patients has the neovascular form of AMD (nAMD) for which therapeutic methods, such as the inhibition of vascular endothelial growth factor (VEGF), have been developed in recent years.(6,7) Dry forms of AMD (dAMD), clinically appearing as drusen (DN) or geographic atroph…”
BackgroundFu, L., Chen, W., Guo, W., Wang, J., Tian, Y., Shi, D., Zhang, X. M., Qiu, H., Xiao, X., Kang, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069240 · Cited by 137
“Vascular endothelial growth factor (VEGF) has been recognized as one of the principal initiators in the development and progression of the vascularization system [32].”
BackgroundApigenin and its impact on gastrointestinal cancers
Lefort, É. C., & Blay, J. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200424 · Cited by 134
Li, Y., Cai, B., Shen, L., Dong, Y., Lu, Q., Sun, S., Liu, S., Ma, S., Ma, P. X., & Chen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.032 · Cited by 129
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.